In Oct. 2016, Catalyst entered into a definitive agreement to sell TC-6499, one of its legacy neuronal nicotinic receptor (NNR) assets that was under development by Targacept prior to its
Growth Capitalist (https://growthcapitalist.com/2018/03/catalyst-biosciences-cbio-reports-1-5-millionmilestone-payments-for-neuronal-nicotinic/)
In Oct. 2016, Catalyst entered into a definitive agreement to sell TC-6499, one of its legacy neuronal nicotinic receptor (NNR) assets that was under development by Targacept prior to its